We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Phospholipase A<sub>2</sub> reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease.
- Authors
Sanchez-Mejia, Rene O.; Newman, John W.; Toh, Sandy; Gui-Qiu Yu; Yungui Zhou; Halabisky, Brian; Cissé, Moustapha; Scearce-Levie, Kimberly; Cheng, Irene H.; Li Gan; Palop, Jorge J.; Bonventre, Joseph V.; Mucke, Lennart
- Abstract
Neuronal expression of familial Alzheimer's disease–mutant human amyloid precursor protein (hAPP) and hAPP-derived amyloid-β (Aβ) peptides causes synaptic dysfunction, inflammation and abnormal cerebrovascular tone in transgenic mice. Fatty acids may be involved in these processes, but their contribution to Alzheimer's disease pathogenesis is uncertain. We used a lipidomics approach to generate a broad profile of fatty acids in brain tissues of hAPP-expressing mice and found an increase in arachidonic acid and its metabolites, suggesting increased activity of the group IV isoform of phospholipase A2 (GIVA-PLA2). The levels of activated GIVA-PLA2 in the hippocampus were increased in individuals with Alzheimer's disease and in hAPP mice. Aβ caused a dose-dependent increase in GIVA-PLA2 phosphorylation in neuronal cultures. Inhibition of GIVA-PLA2 diminished Aβ-induced neurotoxicity. Genetic ablation or reduction of GIVA-PLA2 protected hAPP mice against Aβ-dependent deficits in learning and memory, behavioral alterations and premature mortality. Inhibition of GIVA-PLA2 may be beneficial in the treatment and prevention of Alzheimer's disease.
- Subjects
ALZHEIMER'S disease; PHOSPHOLIPASE A2; ANIMAL models in research; TRANSGENIC mice; NEUROSCIENCES
- Publication
Nature Neuroscience, 2008, Vol 11, Issue 11, p1311
- ISSN
1097-6256
- Publication type
Article
- DOI
10.1038/nn.2213